Osteoporosis International

, Volume 17, Issue 12, pp 1707–1715

Osteoporosis prevention and therapy: preserving and building strength through bone quality


DOI: 10.1007/s00198-006-0187-x

Cite this article as:
Kleerekoper, M. Osteoporos Int (2006) 17: 1707. doi:10.1007/s00198-006-0187-x


While bone mineral density measurements play a central role in osteoporosis management, the degree to which increases in this parameter contribute to bone fragility, fracture risk, and the therapeutic efficacy of osteoporosis agents is controversial. Indeed, bone strength is also significantly dependent upon bone turnover and bone quality, including microarchitecture, mineralization, and geometry. Given the critical role of these factors, it is essential to understand how they are affected by therapeutic agents. Even though a number of technological advances, such as microcomputed tomography, magnetic resonance imaging, and computerized analysis of radiographic patterns, help to provide critical information toward a more comprehensive assessment of bone turnover and bone quality, clinical trials addressing these factors are scarce. This article provides a review of studies relating to how osteoporosis therapies impact parameters of bone strength and quality.


BisphosphonatesCalcitoninEstrogen and SERMsOsteoporosisParathyroid hormone

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2006

Authors and Affiliations

  1. 1.Department of Internal MedicineSaint Joseph Mercy HospitalAnn ArborUSA